Roivant Sciences (ROIV) Accounts Payables (2021 - 2026)
Roivant Sciences (ROIV) posted Accounts Payables of $18.0 million for Q1 2026, up 35.41% on a QoQ basis from $13.3 million in Q4 2025, and down 24.01% year-over-year from $23.7 million in Q1 2025.
Roivant Sciences (ROIV) Accounts Payables (2021 - 2026) Analysis & Trends
Roivant Sciences' Accounts Payables history runs 6 years deep, the most recent figure standing at $18.0 million for Q1 2026.
- Quarterly Accounts Payables fell 24.01% year-over-year to $18.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.0 million (down 24.01% YoY) and the FY2026 annual result came in at $18.0 million, down 24.01% from the prior year.
- Accounts Payables was $18.0 million for Q1 2026 at Roivant Sciences, up from $13.3 million in the prior quarter.
- Across five years, Accounts Payables topped out at $161.3 million in Q2 2022 and bottomed at $11.5 million in Q2 2025.
- A 5-year average of $36.7 million and a median of $27.7 million in 2024 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2022 — Accounts Payables soared 974.36% — and 2023, when it tumbled 68.98%.
- Roivant Sciences' Accounts Payables stood at $48.0 million in 2022, then decreased by 26.61% to $35.2 million in 2023, then sank by 32.69% to $23.7 million in 2024, then tumbled by 43.94% to $13.3 million in 2025, then jumped by 35.41% to $18.0 million in 2026.
- Business Quant data shows ROIV's Accounts Payables at $18.0 million in Q1 2026, $13.3 million in Q4 2025, and $15.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 5.74 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 10.62 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 423.55 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 694,346.76 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 489.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.03 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.52 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 80.54 Mn |
| 10 | Roivant Sciences | 24.35 Bn | 25.12 Bn | - | 18.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.00 Mn |
| Dec 31, 2025 | 13.29 Mn |
| Sep 30, 2025 | 15.06 Mn |
| Jun 30, 2025 | 11.55 Mn |
| Mar 31, 2025 | 23.69 Mn |
| Dec 31, 2024 | 23.71 Mn |
| Sep 30, 2024 | 25.13 Mn |
| Jun 30, 2024 | 27.74 Mn |
| Mar 31, 2024 | 14.03 Mn |
| Dec 31, 2023 | 35.23 Mn |
| Sep 30, 2023 | 44.12 Mn |
| Jun 30, 2023 | 50.04 Mn |
| Mar 31, 2023 | 37.83 Mn |
| Dec 31, 2022 | 48.00 Mn |
| Sep 30, 2022 | 41.36 Mn |
| Jun 30, 2022 | 161.30 Mn |
| Mar 31, 2022 | 34.58 Mn |
| Dec 31, 2021 | 24.36 Mn |
| Sep 30, 2021 | 77.16 Mn |
| Jun 30, 2021 | 15.01 Mn |